Evidence map›Paper›PMID 42084643›Full record

ArticleHerz2026

Transcatheter mitral valve replacement.

Tobias Friedrich Ruf, Theresa Ann-Marie Gößler, Philipp Lurz

Abstract read
PubMed Publisher
In one paragraph

Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tobias Friedrich RufZentrum für Kardiologie, Universitätsmedizin Mainz der Johannes Gutenberg Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. tobias.ruf@unimedizin-mainz.de.
Theresa Ann-Marie GößlerZentrum für Kardiologie, Universitätsmedizin Mainz der Johannes Gutenberg Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
Philipp LurzZentrum für Kardiologie, Universitätsmedizin Mainz der Johannes Gutenberg Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcatheter mitral valve interventions have seen a tremendous and constant increase in use over the past decade. Treatment is mainly aimed at mitral regurgitation (MR), the most common valve disease in industrialized countries. While transcatheter edge-to-edge repair has been established as the main therapy for this pathology, it is not a one-for-all option, and some types of MR would be better addressed using mitral valve replacement. Furthermore, non-rheumatic mitral valve stenosis and mitral annular calcification can only be treated using mitral valve replacement. Yet, although numerous devices have been developed, with some still under investigation in clinical trials, only three devices have received CE marking in the European Union and FDA approval in the United States. This review aims at providing an overview of current dedicated transcatheter mitral valve replacement therapies and those under investigation, while highlighting the indications as well as the potential and limitations of the devices.

Indexed as

Heart Valve ProsthesisMitral Valve InsufficiencyMitral Valve StenosisTranscatheter Mitral Valve ReplacementEvidence-Based MedicineHumansProsthesis DesignTreatment OutcomeDedicated transcatheter devicesInterventional imagingMitral regurgitationMitral valve insufficiencyMitral valve stenosis

Identifiers

PMID42084643

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.